Characteristics and treatment regimens across ERS SHARP severe asthma registries
J. van Bragt (Amsterdam, Netherlands), I. Adcock (London, United Kingdom), G. Anderson (Melbourne, Australia), E. Bel (Amsterdam, Netherlands), G. Braunstahl (Rotterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Busby (Belfast, United Kingdom), G. Canonica (Milan, Italy), H. Cao (East Hanover, NJ, United States of America), K. Chung (London, United Kingdom), Z. Csoma (Budapest, Hungary), D. Davies (Southampton, United Kingdom), B. Dahlen (Huddinge, Sweden), R. Djukanovic (Southampton, United Kingdom), C. Genton (Lausanne, Switzerland), T. Gibson-Latimer (Sheffield, United Kingdom), D. Hamerlijnck (Sheffield, United Kingdom), L. Heaney (Belfast, United Kingdom), E. Heuvelin (Lausanne, Switzerland), I. Horvath (Budapest, Hungary), S. Korn (Mainz, Germany), M. Kots (Parma, Italy), P. Kuna (Lodz, Poland), N. Kwon (Brentford, United Kingdom), R. Louis (Liege, Belgium), R. Naddaf (Amsterdam, Netherlands), V. Plaza (Barcelona, Spain), D. Ramos Barbon (Barcelona, Spain), L. Richards (Amsterdam, Netherlands), S. Skrgat (Golnik, Slovenia), E. Weersink (Amsterdam, Netherlands), V. Yasinska (Huddinge, Sweden), S. Wagers (Maasmechelen, Belgium), A. Maitland-Van Der Zee (Amsterdam, Netherlands)
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Session: Exacerbations and clinical impact of airway diseases
Session type: Oral Presentation
Number: 5354
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. van Bragt (Amsterdam, Netherlands), I. Adcock (London, United Kingdom), G. Anderson (Melbourne, Australia), E. Bel (Amsterdam, Netherlands), G. Braunstahl (Rotterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Busby (Belfast, United Kingdom), G. Canonica (Milan, Italy), H. Cao (East Hanover, NJ, United States of America), K. Chung (London, United Kingdom), Z. Csoma (Budapest, Hungary), D. Davies (Southampton, United Kingdom), B. Dahlen (Huddinge, Sweden), R. Djukanovic (Southampton, United Kingdom), C. Genton (Lausanne, Switzerland), T. Gibson-Latimer (Sheffield, United Kingdom), D. Hamerlijnck (Sheffield, United Kingdom), L. Heaney (Belfast, United Kingdom), E. Heuvelin (Lausanne, Switzerland), I. Horvath (Budapest, Hungary), S. Korn (Mainz, Germany), M. Kots (Parma, Italy), P. Kuna (Lodz, Poland), N. Kwon (Brentford, United Kingdom), R. Louis (Liege, Belgium), R. Naddaf (Amsterdam, Netherlands), V. Plaza (Barcelona, Spain), D. Ramos Barbon (Barcelona, Spain), L. Richards (Amsterdam, Netherlands), S. Skrgat (Golnik, Slovenia), E. Weersink (Amsterdam, Netherlands), V. Yasinska (Huddinge, Sweden), S. Wagers (Maasmechelen, Belgium), A. Maitland-Van Der Zee (Amsterdam, Netherlands). Characteristics and treatment regimens across ERS SHARP severe asthma registries. 5354
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: